In this short perspective piece, Julia calls for more focus on investing in the social infrastructure and systems of support that might reduce harm and, “ensure availability, affordability, and viability for all stakeholders, especially prioritizing support for practitioners.”
- May 2023
- In this short piece, Adelaide Wilcox King shares her experience of introducing a new capstone course, Reimagining Capitalism and the Purpose-Driven Firm, which uses the emergent psychedelics industry as a case study.
- VANCOUVER, British Columbia, Jan. 26, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce the engagement of Bloom Burton Securities Inc. (“Bloom Burton”) for strategic advisory […]
- Here, we review how psychedelics companies adapted their operations throughout 2022, including a look at M&A, licensing and partnerships.
- We present the results of our second Psychedelic Investor Pulse Survey, focusing on any changes that have emerged between the two surveys.
- No more posts to load